TrialBreast cancer research and treatment2022

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.

Nicholas Turner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.